Efficient growth inhibition of EGFR over-expressing tumor cells by an anti-EGFR nanobody

Molecular Biology Reports

Volumn 40, Issue 12, 2013, Pages 6737-6745

  Omidfar, Kobra ^a   Amjad Zanjani, Fatemeh Sadat ^a   Hagh, Arghavan Golbaz ^a   Azizi, Maedeh Darziani ^a   Rasouli, Seyed Javad ^a   Kashanian, Susan ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

EGFR; Growth inhibition; Nanobody; Targeted therapy

Indexed keywords

NANOBODY; NANOBODY OA CB6; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR;

ANIMAL EXPERIMENT; ARTICLE; BREAST CANCER; CANCER CELL; CANCER INHIBITION; CELL PROLIFERATION; CELL SURFACE; CONTROLLED STUDY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; MALE; NONHUMAN; PROTEIN EXPRESSION; RECEPTOR BINDING; SQUAMOUS CELL CARCINOMA; WESTERN BLOTTING;

ANIMALS; ANTIBODY AFFINITY; ANTIBODY SPECIFICITY; CAMELS; CELL LINE, TUMOR; CELL PROLIFERATION; ELECTROPHORESIS, POLYACRYLAMIDE GEL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HUMANS; IMMUNITY, HUMORAL; NEOPLASMS; RECEPTOR, EPIDERMAL GROWTH FACTOR; SINGLE-DOMAIN ANTIBODIES;

EID: 84890339509     PISSN: 03014851     EISSN: 15734978     Source Type: Journal    
DOI: 10.1007/s11033-013-2790-1     Document Type: Article

References (34)

1. Alroy I, Yarden Y (1997) The ErbB signaling network in embryogenesis and oncogenesis: signal diversification through combinatorial ligand/receptor interactions. FEBS Lett 410(1):83-86
2. Citri A, Yarden Y (2006) EGF-ERBB signaling: towards the systems level. Nat Rev Mol Cell Biol 7:505-516
3. Baselga J (2002) Why the epidermal growth factor receptor? The rationale for cancer therapy. Oncologist 7(suppl 4):2-8
4. Aerts HJ, Dubois L, Hackeng TM, Straathof R, Chiu RK, Lieuwes NG, Jutten B, Weppler SA, Lammering G, Wouters BG, Lambin P (2007) Development and evaluation of a cetuximab-based imaging probe to target EGFR and EGFRvIII. Radiother Oncol 83:326-332
5. Boland W, Bebb G (2009) Nimotuzumab: a novel anti- EGFR monoclonal antibody that retains anti-EGFR activity while minimizing skin toxicity. Expert Opin Biol 9:1199-1206
6. Cohenuram M, Saif MW (2007) Panitumumab the first fully human monoclonal antibody: from the bench to the clinic. Anticancer Drugs 18(1):7-15
7. Ciardiello F, Tortora G (2008) EGFR antagonists in cancer treatment. N Engl J Med 358:1160-1174
8. Imai K, Takaoka A (2006) Comparing antibody and small molecule therapies for cancer. Nat Rev Cancer 6:714-727
9. Altintas I, Kok RJ, Schiffelers RM (2012) Targeting epidermal growth factor receptor in tumors: from conventional monoclonal antibodies via heavy chain-only antibodies to nanobodies. Eur J Pharm Sci 45:399-407
10. Dienstmann R, Tabernero J (2010) Necitumumab, a fully human IgG1 mAb directed against the EGFR for the potential treatment of cancer. Curr Opin Invest Drugs 11:1434-1441
11. Graeven U, Kremer B, Sudhoff T, Killing B, Rojo F, Weber D, Tillner J, Unal C, Schmiege W (2006) Phase I study of the humanized anti-EGFR monoclonal antibody matuzumab (EMD 72000) combined with gemcitabine in advanced pancreatic cancer. Br J Cancer 94:1293-1299
12. Martinelli E, Palma RD, Orditura M, Vita FD, Ciardiello F (2009) Anti-epidermal growth factor receptor monoclonal antibodies in cancer therapy. Clin Exp Immunol 158(1):1-9
13. Omidfar K, Shirvani Z (2012) Single domain antibodies: a new concept for epidermal growth factor receptor and EGFRvIII targeting. DNA Cell Biol 31(6):1015-1026
14. Roovers RC, Laeremans T, Huang L, De Taeye S, Verkleij AJ, Revets H, de Haard HJ, van Bergen en Henegouwen PMP (2007) Efficient inhibition of EGFR signaling and of tumour growth by antagonistic anti-EFGR nanobodies. Cancer Immunol Immunother 56:303-317
15. Deffar K, Shi H, Li L, Wang X, Zhu X (2009) Nanobodies the new concept in antibody engineering. Afr J Biotechnol 8:2645-2652
16. Dumoulin M, Conrath K, Van Meirhaeghe A, Meersman F, Heremans K, Frenken LG, Muyldermans S, Wyns L, Matagne A (2002) Single-domain antibody fragments with high conformational stability. Protein Sci 11:500-515
17. Hamers-Casterman C, Atarhouch T, Muyldermans S, Robinson G, Hammers C, Songa EB, Bendahman N, Hammers R (1993) Naturally occurring antibodies devoid of light chains. Nature 363:446-448
18. Muyldermans S (2001) Single domain camel antibodies: current status. Rev Mol Biotechnol 74:277-302
19. Omidfar K, Rasaee MJ, Kashanian S, Paknejad M, Bathaie Z (2007) Studies of thermostability in camelusbactrianus (Bactrian camel) single-domain antibody specific for the mutant epidermal-growth-factor receptor expressed by Pichia. Biotechnol Appl Biochem 46:41-49
20. Kolkman JA, Law DA (2010) Nanobodies - from llamas to therapeutic proteins. Drug Discov Today Technol 7:139-146
21. Omidfar K, Moinfar Z, Naderi Sohi A, Tavangar SM, Haghpanah V, Heshmat R, Larijani B (2009) Expression of EGFRvIII in thyroid carcinoma: immunohistochemical study by camel antibodies. Immunol Invest 38:165-180
22. Stijlemans B, Conrath K, Cortez-Retamozo V, Van Xong H, Wyns L, Senter P, Tillib SV (2011) Camel nanoantibody is an efficient tool for research, diagnostics and therapy. Mol Biol 45:77-85
23. Evazalipour M, SoltaniTehrani B, Abolhassani M, Morovvati H, Omidfar K (2012) Camel heavy chain antibodies against prostate-specific membrane antigen. DNA Cell Biol 31:424-429
24. Omidfar K, Rasaee MJ, Modjtahedi H, Forouzandeh M, Taghikhani M, Bakhtiari A, Paknejad M, Kashanian S (2004) Production and chacterization of a new antibody specific for the mutant EGF receptor, EGFRvIII, in Camelus bactrianus. Tumour Biol 25:179-187
25. Omidfar K, Rasaee MJ, Modjtahedi H, Forouzandeh M, Taghikhani M, Golmakani N (2004) Production of a novel camel single domain antibody specific for the type III mutant EGFR. Tumour Biol 25:296-305
26. Tege H, Tourle S, Ottosson J, Persson A (2010) Increased levels of recombinant human proteins with the Escherichia coli strain Rosetta (DE3). Protein Expr Purif 69:159-167
27. Beatty JD, Beatty BG, Vlahos WG (1987) Measurement of monoclonal antibody affinity by non-competitive enzyme immunoassay. J Immunol Methods 100:173-179
28. Cunningham MP, Thomas H, Fan Z, Modjtahed H (2006) Responses of human colorectal tumor cells to treatment with the anti-epidermal growth factor receptor monoclonal antibody ICR62 used alone and in combination with the EGFR tyrosine kinase inhibitor gefitinib. Cancer Res 66(15):7708-7715
29. Wykosky J, Fenton T, Furnari F, Cavenee WK (2011) Therapeutic targeting of epidermal growth factor receptor in human cancer: successes and limitations. Chin J Cancer 30:5-12
30. Beckman RA, Weiner LM, Davis HM (2007) Antibody constructs in cancer therapy: protein engineering strategies to improve exposure in solid tumors. Cancer 109:170-179
31. Elbakri A, Nelson PN, Abu Odeh RO (2010) The state of antibody therapy. Hum Immunol 71:1243-1250
32. Omidfar K, Khorsand F, Darziani Azizi M (2013) New analytical applications of gold nanoparticles as label in antibody based sensors. Biosensor and Bioelectronic 43:336-347
33. Behdani M, Zeinali S, Khanahmad H, Karimipour M, Asadzadeh N, Azadmanesh K, Khabiri A, Schoonooghed S, HabibiAnbouhi M, Hassanzadeh-Ghassabehd G, Muyldermans S (2012) Generation and characterization of a functional nanobody against the vascular endothelial growth factor receptor-2; angiogenesis cell receptor. Mol Immunol 50:35-41
34. Oliveira S, Schiffelers RM, van der Veeken J, van der Meel R, Vongpromek R, van Bergen en Henegouwen PMP, Storm G, Roovers RC (2010) Down regulation of EGFR by a novel multivalent nanobody-liposome platform. J Controlled Release 145:165-175